| Ticker Details |
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
|
| IPO Date: |
December 1, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$574.04M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.57 | 2.30%
|
| Avg Daily Range (30 D): |
$0.28 | 2.42%
|
| Avg Daily Range (90 D): |
$0.30 | 2.71%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
.61M |
| Avg Daily Volume (90 D): |
.79M |
| Trade Size |
| Avg Trade Size (Sh.): |
110 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
71 |
| Institutional Trades |
| Total Institutional Trades: |
5,022 |
| Avg Institutional Trade: |
$2.49M |
| Avg Institutional Trade (30 D): |
$1.4M |
| Avg Institutional Trade (90 D): |
$1.32M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.16M |
| Avg Closing Trade (30 D): |
$.88M |
| Avg Closing Trade (90 D): |
$1.2M |
| Avg Closing Volume: |
108.57K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$1.42
|
$.96
|
$-.22
|
|
Diluted EPS
|
$1.33
|
$.91
|
$-.22
|
|
Revenue
|
$788.9M
|
$231.1M
|
$140.9M
|
|
Gross Profit
|
|
$145.2M
|
$74M
|
|
Net Income / Loss
|
$75.9M
|
$51.2M
|
$-12M
|
|
Operating Income / Loss
|
$118.5M
|
$76.5M
|
$1.6M
|
|
Cost of Revenue
|
|
$85.9M
|
$66.9M
|
|
Net Cash Flow
|
$92.8M
|
$-21.8M
|
$118.2M
|
|
PE Ratio
|
8.24
|
|
|
|
|
|
